Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 9,364 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions: Cabiralizumab, Nivolumab; Biological
Lead sponsor: Five Prime Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 39
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more

Conditions: Multiple Sclerosis
Interventions: Assistive Device Training; Behavioral
Lead sponsor: Portland VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Active Polyarticular Juvenile Idiopathic Arthritis
Interventions: Abatacept; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 12
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more

Conditions: Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
Interventions: Cohort 1, Cohort 2, Cohort 3, Antibiotics; Biological · Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: Brexpiprazole, Seroquel XR, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more

Conditions: Malignant Melanoma
Interventions: HF10 plus Ipilimumab; Biological
Lead sponsor: Takara Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Francisco, California • Atlanta, Georgia • Portland, Oregon + 5 more

Conditions: Hypercholesterolemia
Interventions: Disodium Ascorbyl Phytostanol Phosphate (FM-VP4); Drug
Lead sponsor: Forbes Medi-Tech; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Timeline: Started 2005
U.S. locations: 14
States / cities: Mobile, Alabama • San Diego, California • Daytona Beach, Florida + 10 more

Conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Neratinib Maleate, Palbociclib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 193
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 154 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 889
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, keyhole limpet hemocyanin, sargramostim, cyclophosphamide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Genitope Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 21
States / cities: Dublin, California • Greenbrae, California • Los Angeles, California + 16 more

Conditions: Adult Brain Glioblastoma
Interventions: Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pseudobulbar Affect (PBA)
Interventions: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 45
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more

Conditions: Bleeding
Interventions: TachoSil®, Surgicel® Original; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more

Conditions: Sleep Apnea, Gastroesophageal Reflux Disease
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atopic Dermatitis
Interventions: Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years to 43 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: San Diego, California • Denver, Colorado • Portland, Oregon

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 226
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more

Conditions: Uveitis, Anterior, Panuveitis
Interventions: Placebo, LX211; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 14
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 11 more

Conditions: Menopausal and Female Climacteric States
Interventions: Other: Placebo, GSK232802, PREMARIN; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more

Conditions: Alopecia, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Carcinoma, Renal Cell
Interventions: Belzutifan, Everolimus; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Multiple Sclerosis, Optic Neuritis
Interventions: Methylprednisolone, Prednisone; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 46 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1988
U.S. locations: 15
States / cities: Little Rock, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CAPTURE Tool; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 80 Years
Enrollment: 4,679 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 4 more

Conditions: Pancreatic Cancer
Interventions: Tarceva (erlotinib HCl, OSI-774); Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 60
States / cities: Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 51 more

Search by objective public record fields.

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Assistive Device Training in Multiple Sclerosis

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Phase I Study of Safety and Immunogenicity of ADU-623

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Effect of Continuous Positive Airway Pressure (CPAP) on Lower Esophageal Sphincter Pressure in Morbidly Obese Patients

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Optic Neuritis Treatment Trial (ONTT)

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 1)

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.